Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric study of IVIG-SN for primary humoral immunodeficiency
MOH_2018-11-01_004729Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of IVIg-SN 10% in Primary antibody deficiency (PAD), agammaglobulinemia and hypogammaglobulinemia, sponsored by GC Biopharma. Started Oct 2018; status: completed.
02
Drugs
IVIg-SN 10%
03
Conditions
Primary antibody deficiency (PAD)agammaglobulinemiahypogammaglobulinemia
Beyond the preview
Go deeper on MOH_2018-11-01_004729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-01_004729.